ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Potassium Chloride

Also written as “Custodiol”, “HalfLytely” and “PLENVU®”.

Its studies are mostly in Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 3 companies.

Drug pagePotassium Chloride: every studyAll 43 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 14, 20148 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. F. Köhler Chemie41 open or runningphase 3since Feb 14, 2014Sep 29, 2011Jan 2027phase 2 · NCT06032195
Sebela Pharmaceuticalsits history only30 open or runningphase 4since Sep 9, 2005Sep 9, 2005none ahead
Norgineits history only11 open or runningphase 3since Oct 16, 2025Oct 16, 2025Jan 6, 2027phase 3 · NCT07218523

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr. F. Köhler Chemie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2011First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT01444235 · 102 enrolled · Germany
  2. Feb 14, 2014Phase 3 study in Aortic Valve DiseaseNCT02098772 · 530 enrolled · Germany
  3. Aug 11, 2015Phase 3 study in Heart FailureNCT02869022 · 105 enrolled · Austria, Germany
  4. Aug 21, 2023Phase 2 study in Heart TransplantationNCT06032195 · 15 planned · Germany

Ahead

  1. Jan 2027Primary completion: phase 2 study in Heart TransplantationNCT06032195

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Dr. F. Köhler Chemie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06032195Heart Transplantation · Germany2RecruitingJan 202715
NCT02869022Heart Failure · Austria, Germany3CompletedSep 2, 2019105
NCT02098772Aortic Valve Disease · Germany3CompletedNov 16, 2018530
NCT01444235Coronary Artery Disease · Germany2CompletedMay 2012102

How it is read

Names in the registry

  • “Custodiol”, 4 entries
  • “HalfLytely”, 3 entries
  • “PLENVU®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.